Cardiovascular Results For Dapagliflozin Point To Sglt2 Use To Prevent Heart Failure | Latest News RSS feed

Cardiovascular Results For Dapagliflozin Point To Sglt2 Use To Prevent Heart Failure - Latest News

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

Results presented at the American Heart Association in Chicago provided the strongest evidence to date on what heart failure specialists have discussed for several years now: the possibility that SGLT... read more

New CARMELINA Analysis: No Heart Failure Risk With Linagliptin

Patients with type 2 diabetes who are at high cardiovascular risk do not have an increased likelihood of heart failure ... another SGLT2 inhibitor, dapagliflozin (Farxiga/Forxiga, AstraZeneca), or pla... read more

Significantly reduced cardiovascular complications in patient population with type 2 diabetes announced in landmark DECLARE-TIMI 58 trial

AstraZeneca releases full results ... Dapagliflozin significantly reduced the composite endpoint of risk of hospitalisation for heart failure & cardiovascular death vs. placebo by 17%. DECLARE-TIMI 58 ... read more

Looking for another news?

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association ...

Amarin Corporation PLC (NASDAQ:AMRN) Primary REDUCE-IT Trial Results ... for lower heart disease but they don't cardiovascular a total mortality. Some did. On the issue of the use of mineral ... read more

AstraZeneca to present scientific advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions

AstraZeneca will also present analyses from DURATION-8, evaluating the investigational use of exenatide extended-release in combination with dapagliflozin ... Heart Failure and Death in New Users of S... read more

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes

"We found that the benefit of dapagliflozin on heart failure ... cardiovascular events in patients with established heart disease." He also points out that the adverse effects and costs of the SGLT2 i... read more

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

This 6,000-patient study is testing ezetimibe to prevent cerebrovascular and cardiovascular events ... CV death or hospitalization for heart failure with the selective sodium glucose co-transport 2 (S... read more

Top heart disease and stroke research advances of 2017

Economic recession affects the cardiovascular ... heart failure for people with diabetes A large international study in Circulation showed lower rates of death and heart failure for diabetes patients ... read more

Study: Type 2 diabetes pill Jardiance cuts risk of death

The study found Jardiance reduced deaths from heart complications by 38 percent, deaths from any cause by 32 percent and hospitalizations due to chronic heart failure ... sugar to trying to prevent ca... read more

Cardiovascular Radiance For Jardiance

It seems likeliest that the result points to an effect common to all the SGLT2 inhibitors, but until the cardiovascular outcomes studies ... such as hospitalisation for heart failure and diabetes keto... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us